The role of PTEN in prostate cancer cell tropism to the bone micro-environment

Carcinogenesis

Volumn 28, Issue 7, 2007, Pages 1393-1400

  Wu, Z ^a   McRoberts, K S ^a   Theodorescu, D ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOCAL ADHESION KINASE; LIPID; PHOSPHATASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN CDC42; RAC1 PROTEIN;

ANIMAL CELL; ARTICLE; BLADDER CANCER; BONE METASTASIS; CALVARIA; CANCER CELL CULTURE; CARCINOGENESIS; CELL MIGRATION; CELL MOTILITY; CELL STRAIN LNCAP; CONTROLLED STUDY; CULTURE MEDIUM; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LUNG ALVEOLUS CELL; LUNG FIBROBLAST; MOUSE; NONHUMAN; NULL CELL; OSTEOBLAST; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN INDUCTION;

ANIMALS; BONE NEOPLASMS; CDC42 GTP-BINDING PROTEIN; CELL LINE, TUMOR; CHEMOTAXIS; CULTURE MEDIA, CONDITIONED; ENZYME ACTIVATION; FIBROBLASTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG; MALE; MICE; NEOPLASM INVASIVENESS; ORGAN SPECIFICITY; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE; RAC1 GTP-BINDING PROTEIN; SKULL;

EID: 34547777444     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgm050     Document Type: Article

References (68)

1. Loberg,R.D. et al. (2005) Pathogenesis and treatment of prostate cancer bone metastases: Targeting the lethal phenotype. J. Clin. Oncol., 23, 8232-8241.
2. Resnick,M.I. (1992) Hemodynamics of prostate cancer bone metastases. Adv. Exp. Med. Biol., 324, 77-81.
3. Logothetis,C.J. et al. (2005) Osteoblasts in prostate cancer metastasis to bone. Nat. Rev. Cancer, 5, 21-28.
4. Saad,F. et al. (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J. Natl Cancer Inst., 96 879-882.
5. Jimeno,A. et al. (2005) Atrasentan: A novel and rationally designed therapeutic alternative in the management of cancer. Expert Rev. Anticancer Ther., 5, 419-427.
6. Sikes,R.A. et al. (2004) Cellular interactions in the tropism of prostate cancer to bone. Int. J. Cancer, 110, 497-503.
7. Cher,M.L. et al. (2003) Maspin expression inhibits osteolysis, tumor growth, and angiogenesis in a model of prostate cancer bone metastasis. Proc. Natl Acad. Sci. USA, 100, 7847-7852.
8. Keller,E.T. et al. (2001) Prostate carcinoma skeletal metastases: cross-talk between tumor and bone. Cancer Metastasis Rev., 20 333-349.
9. LaTulippe,E. et al. (2002) Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res., 62, 4499-4506.
10. Jacob,K. et al. (1999) Osteonectin promotes prostate cancer cell migration and invasion: A possible mechanism for metastasis to bone. Cancer Res., 59, 4453-4457.
11. Stambolic,V. et al. (1999) Modulation of cellular apoptotic potential: Contributions to oncogenesis. Oncogene, 18, 6094-6103.
12. Ali,I.U. et al. (1999) Mutational spectra of PTEN/MMAC1 gene: A tumor suppressor with lipid phosphatase activity. J. Natl Cancer Inst., 91, 1922-1932.
13. Ittmann,M.M. (1998) Chromosome 10 alterations in prostate adenocarcinoma (review). Oncol. Rep., 5, 1329-1335.
14. Vlietstra,R.J. et al. (1998) Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res., 58, 2720-2723.
15. Abate-Shen,C. et al. (2000) Molecular genetics of prostate cancer. Genes Dev., 14, 2410-2434.
16. Dreher,T. et al. (2004) Reduction of PTEN and p27kip1 expression correlates with tumor grade in prostate cancer. Analysis in radical prostatectomy specimens and needle biopsies. Virchows Arch., 444, 509-517.
17. McMenamin,M.E. et al. (1999) Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res., 59, 4291-4296.
18. Suzuki,H. et al. (1998) Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res., 58, 204-209.
19. Depowski,P.L. et al. (2001) Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer. Mod. Fathol., 14, 672-676.
20. Kanamori,Y. et al. (2002) PTEN expression is associated with prognosis for patients with advanced endometrial carcinoma undergoing postoperative chemotherapy. Int. J. Cancer, 100, 686-689.
21. Wang,S. et al. (2003) Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell, 4, 209-221.
22. Trotman,L.C. et al. (2003) Pten dose dictates cancer progression in the prostate. PLoS Biol., 1, E59.
23. Backman,S.A. et al. (2004) Early onset of neoplasia in the prostate and skin of mice with tissue-specific deletion of Pten. Proc. Natl Acad. Sci. USA, 101, 1725-1730.
24. Wu,Z. et al. (2006) Conditional expression of PTEN alters the androgen responsiveness of prostate cancer cells. Prostate, 66 1114-1123.
25. Gildea,J.J. et al. (2000) Genetic and phenotypic changes associated with the acquisition of tumorigenicity in human bladder cancer. Genes Chromosomes Cancer, 27, 252-263.
26. Gildea,J.J. et al. (2002) RhoGDI2 is an invasion and metastasis suppressor gene in human cancer. Cancer Res., 62, 6418-6423.
27. Qiu,R.G. et al. (1995) An essential role for Rac in Ras transformation. Nature, 374, 457-459.
28. Qiu,R.G. et al. (1997) Cdc42 regulates anchorage-independent growth and is necessary for Ras transformation. Mol. Cell. Biol., 17, 3449-3458.
29. Taylor,J.M. et al. (2000) A role for focal adhesion kinase in phenylephrine-induced hypertrophy of rat ventricular cardiomyocytes. J. Biol. Chem., 275, 19250-19257.
30. Wong,G.L. et al. (1975) Target cells in bone for parathormone and calcitonin are different: Enrichment for each cell type by sequential digestion of mouse calvaria and selective adhesion to polymeric surfaces. Proc. Natl Acad. Sci. USA, 72, 3167-3171.
31. Gildea,J.J. et al. (2002) The role of Ra1 A in epidermal growth factor receptor-regulated cell motility. Cancer Res., 62, 982-985.
32. Dhamija,S. et al. (1999) Cloning and characterization of the murine ameloblastin promoter. J. Biol. Chem., 274, 20739-20743.
33. Wu,T.T. et al. (1998) Establishing human prostate cancer cell xenografts in bone: Induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LnCap and lineage-derived metastatic sublines. Int. J. Cancer 77, 887-894.
34. Kaighn,M.E. et al. (1979) Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest. Urol., 17 16-23.
35. Victor,R. et al. (1999) Human breast-cancer metastasis formation in a nude-mouse model: Studies of hyaluronidase, hyaluronan and hyaluronan-binding sites in metastatic cells. Int. J. Cancer, 82, 77-83.
36. Crowley,C.W. et al. (1993) Prevention of metastasis by inhibition of the urokinase receptor. Proc. Natl Acad. Sci. USA, 90, 5021-5025.
37. Harding,M.A. et al. (2002) Functional genomic comparison of lineage-related human bladder cancer cell lines with differing tumorigenic and metastatic potentials by spectral karyotyping, comparative genomic hybridization, and a novel method of positional expression profiling. Cancer Res., 62, 6981-6989.
38. van Bokhoven,A. et al. (2001) TSU-Pr1 and JCA-1 cells are derivatives of T24 bladder carcinoma cells and are not of prostatic origin. Cancer Res., 61, 6340-6344.
39. Gu,J. et al. (1999) Shc and FAK differentially, regulate cell motility and directionality modulated by PTEN. J. Cell Biol., 146, 389-403.
40. Tamura,M. et al. (1999) Tumor suppressor PTEN inhibition of cell invasion, migration, and growth: Differential involvement of focal adhesion kinase and p130Cas. Cancer Res., 59, 442-449.
41. Tamura,M. et al. (1998) Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science, 280, 1614-1617.
42. Ilic,D. et al. (1995) Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice. Nature 377, 539-544.
43. Cary,L.A. et al. (1996) Stimulation of cell migration by overexpression of focal adhesion kinase and its association with Src and Fyn. J. Cell Sci., 109 (Pt 7), 1797-1794.
44. Han,J. et al. (1998) Role of substrates and products of PI 3-kinase in regulating activation of Rac-related guanosine triphosphatases by Vav. Science, 279, 558-560.
45. Van Aelst,L. et al. (1997) Rho GTPases and signaling networks. Genes Dev., 11, 2295-2322.
46. Benard,V. et al. (1999) Characterization of rac and cdc42 activation in chemoattractant-stimulated human neutrophils using a novel assay for active GTPases. J. Biol. Chem., 274, 13198-13204.
47. Paget,S. (1989) The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev., 8, 98-101.
48. Hart,I.R. (1982) 'Seed and soil' revisited: Mechanisms of site-specific metastasis. Cancer Metastasis Rev., 1, 5-16.
49. Festuccia,C. et al. (1999) Osteoblast conditioned media contain TGF-beta1 and modulate the migration of prostate tumor cells and their interactions with extracellular matrix components. Int. J. Cancer, 81, 395-403.
50. Festuccia,C. et al. (1999) Osteoblasts modulate secretion of urokinase-type plasminogen activator (uPA) and matrix metalloproteinase-9 (MMP-9) in human prostate cancer cells promoting migration and matrigel invasion. Oncol. Res., 11, 17-31.
51. Posta,G. et al. (1980) The pathogenesis of cancer metastasis. Nature, 283, 139-146.
52. Fidler,J.J. (2002) The organ microenvironment and cancer metastasis. Differentiation, 70, 498-505.
53. Pinski,J. et al. (2001) Therapeutic implications of enhanced G(0)/ G(1) checkpoint control induced by coculture of prostate cancer cells with osteoblasts. Cancer Res., 61, 6372-6376.
54. Gao,P. et al. (2005) Negative regulation of CXCR4-mediated chemotaxis by the lipid phosphatase activity of tumor suppressor PTEN. Blood, 106, 2619-2626.
55. Liliental,J. et al. (2000) Genetic deletion of the Pten tumor suppressor gene promotes cell motility by activation of Rac1 and Cdc42 GTPases. Curr. Biol., 10, 401-404.
56. Merlot,S. et al. (2003) Leading the way: Directional sensing through phosphatidylinositol 3-kinase and other signaling pathways. J. Cell Sci., 116, 3471-3478.
57. Ward,S.G. (2004) Do phosphoinositide 3-kinases direct lymphocyte navigation? Trends Immunol., 25, 67-74.
58. Theodorescu,D. et al. (1998) Epidermal growth factor receptor-regulated human bladder cancer motility is in part a phosphatidylinositol 3-kinase-mediated process. Cell Growth Differ. 9, 919-928.
59. Hall,A. (1998) Rho GTPases and the actin cytoskeleton. Science, 279, 509-514.
60. Higuchi,M. et al. (2001) Akt mediates Rac/Cdc42-regulated cell motility in growth factor-stimulated cells and in invasive PTEN knockout cells. Curr. Biol., 11, 1958-1962.
61. Raftopoulou,M. et al. (2004) Cell migration: Rho GTPases lead the way. Dev. Biol., 265, 23-32.
62. Banyard,J. et al. (2000) Motility and invasion are differentially modulated by Rho family GTPases. Oncogene, 19, 580-591.
63. Paruchuri,S. et al. (2005) The pro-inflammatory mediator leukotriene D4 induces phosphatidylinositol 3-kinase and Rac-dependent migration of intestinal epithelial cells. J. Biol. Chem., 280 13538-13544.
64. Das,R. et al. (2003) Osteopontin stimulates cell motility and nuclear factor kappaB-mediated secretion of urokinase type plasminogen activator through phosphatidylinositol 3-kinase/Akt signaling pathways in breast cancer cells. J. Biol. Chem., 278, 28593-28606.
65. Sung,V. et al. (1998) Bone sialoprotein supports breast cancer cell adhesion proliferation and migration through differential usage of the alpha(v)beta3 and alpha(v)beta5 integrins. J. Cell. Physiol., 176, 482-494.
66. Chandrasekaran,S. et al. (1999) Pro-adhesive and chemotactic activities of thrombospondin-1 for breast carcinoma cells are mediated by alpha3beta1 integrin and regulated by insulin-like growth factor-1 and CD98. J. Biol. Chem., 274, 11408-11416.
67. Wass,J.A. et al. (1981) Responses of normal and malignant cells to collagen, collagen-derived peptides and the C5-related tumor cell chemotactic peptide. Cell Differ., 10, 329-332.
68. De,S. et al. (2003) Molecular pathway for cancer metastasis to bone. J. Biol. Chem., 278, 39044-39050.